ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease.
Hilgers
Karl F
KF
*Department of Medicine IV, University of Erlangen-Nürnberg, Nürnberg, Germany; Department of Medicine VI, Schwabing General Hospital, Ludwig-Maximilians-University, Munich, Germany; and German Institute for High Blood Pressure Research, Heidelberg, Germany.
Mann
Johannes F E
JFE
*Department of Medicine IV, University of Erlangen-Nürnberg, Nürnberg, Germany; Department of Medicine VI, Schwabing General Hospital, Ludwig-Maximilians-University, Munich, Germany; and German Institute for High Blood Pressure Research, Heidelberg, Germany.
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002908:Chronic Disease; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000188:drug therapy*; D044140:Receptor, Angiotensin, Type 1
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D044140:Receptor, Angiotensin, Type 1